Source: Sponsors pharmacoeconomic submission 1 Table 9: Summary of the Sponsors Economic Evaluation Results for Third-Line Treatment ICER = incremental cost-effectiveness ratio
Wegovy weight-loss drug reduced risk of serious heart problems by 20%, study finds The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20%, according to a large, international study paid for by Novo Nordisk, the drugmaker behind the product
However, you may begin experiencing weight loss after only around a month
Cost and the question of how public programs should prioritize competing needs are genuine concerns
When I went through the quiz, I was qualified
Cognitive Clarity & Mood: Sharpen focus, improve mood, and support long-term brain health